logo
Share SHARE
FONT-SIZE Plus   Neg

Lorus Therapeutics Receives Patent Approval For Anticancer Drug LOR-253

Lorus Therapeutics Inc. (LOR.TO) said Wednesday it has got the approval of the U.S. Patent and Trademark Office for its patent regarding the lead small molecule anticancer drug LOR-253.

The patent, which was originally set to expire in May 2026, was granted a patent adjustment that extends its expiry date to February 2028.

The US patent covers LOR-253 composition of matter and methods of treating cancer. Patents with similar protection for LOR-253 have been issued in Canada and Australia, and are pending in Europe, Japan, and China.

LOR-253 is in a Phase I clinical trial that assesses the safety profile and antitumor activity of LOR-253. Patients with advanced or metastatic solid tumors who are unresponsive to conventional therapy, or for which no effective therapy is available, are currently being recruited for this clinical study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A new species of 'super-armored' worm, almost bizarre beyond description, has been discovered. Good thing this one's no longer around. Stocks moved sharply lower over the course of the trading day on Monday amid continued concerns about Greece and the possibility the debt-laden country will exit the eurozone. With the steep drop on the day, the Dow fell to its lowest closing level in almost five months. The most "American" vehicle isn't Built Ford Tough. It's not in jingles sung by John Mellencamp or Bob Seger, and it probably isn't kickin' up backroads dust somewhere in the Heartland.
comments powered by Disqus
Follow RTT